1. What is CJC-1295 without DAC?
CJC-1295 without DAC, also called Modified GRF (1-29), is a synthetic growth hormone–releasing hormone (GHRH) analog composed of 30 amino acids. It was designed to provide improved stability compared to native GHRH while maintaining a short-acting profile. Unlike its DAC-linked counterpart, it has a relatively brief half-life and has been studied in research settings for its ability to stimulate pulsatile growth hormone (GH) release.
2. CJC-1295 without DAC Structure
Sequence:Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-GIn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-GIn-Leu-Ser-Ala-Arg-Lys-Leu-Leu-GIn-Asp-lle-Leu-Ser-Arg-NH2
Molecular formula:C₁₅₂H₂₅₂N₄₄O₄₂
Molar Mass: 3367.9g/mol
Synonyms: Mod GRF 1-29, CJC-1295 no DAC
3. CJC-1295 without DAC Research
Research Overview
CJC-1295 without DAC has been investigated as a tetra-substituted analog of GHRH (1-29). These substitutions increase resistance to enzymatic breakdown, giving it greater stability than native GHRH while still allowing for transient, pulsatile GH stimulation 【1】.
【1】 Mechanism of Action
CJC-1295 without DAC binds to GHRH receptors in the anterior pituitary and stimulates growth hormone release in a pulsatile manner, more closely resembling natural GH secretion rhythms 【2】. This pulsatility has been of interest in experimental research because it may avoid receptor desensitization associated with prolonged stimulation.
【2】 Comparative Properties
|
Peptide
|
Half-Life
|
Research Context
|
Notes
|
|
CJC-1295 (No DAC)
|
~30 min
|
GH pulse studies
|
Mimics physiological secretion patterns
|
|
CJC-1295 (With DAC)
|
~7–10 days
|
Long-acting analog
|
Provides prolonged GH elevation
|
|
Ipamorelin
|
~2 h
|
GH secretagogue research
|
Sometimes studied in combination
|
【3】 Research Applications
Research contexts for CJC-1295 without DAC include:
l Studies on GH secretion dynamics
l Evaluation of short-acting vs long-acting GHRH analogs
l Synergy research with other GH secretagogues such as Ipamorelin 【3】
4. Future CJC-1295 without DAC Research
Future investigations are expected to focus on:
l Optimizing pulsatile GH stimulation
Research suggests pulsatile GH secretion may be more physiologically favorable than sustained elevation, potentially maintaining receptor sensitivity 【4】.
l Comparative studies
CJC-1295 without DAC may be compared with DAC-linked CJC-1295, Tesamorelin, and other secretagogues to better understand half-life differences, receptor activity, and safety profiles.
l Endocrine and aging models
Interest exists in studying how short-acting GHRH analogs might contribute to research on endocrine regulation, circadian rhythms, and age-related GH decline.
l Delivery approaches
Future studies may explore alternative delivery systems (e.g., sublingual or transdermal) to optimize bioavailability in experimental contexts.
5. Application Area
CJC-1295 without DAC is primarily studied in:
l 🧪 Laboratory research on GH-releasing hormone analogs
l ⏳ Endocrine regulation and aging research models
l 🧬 Comparative pharmacology of peptide half-lives
l 🧠 Neuroendocrine and circadian rhythm investigations
Its short half-life allows controlled GH stimulation experiments without sustained exposure, making it a tool of interest in intermittent GH secretion studies.
⚠ Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
